German Billionaire Dietmar Hopp Backs CureVac Further
This article was originally published in The Pink Sheet Daily
Executive Summary
Billionaire Dietmar Hopp’s latest CureVac injection – €80 million ($105 million) – is the biggest private financing ever given to a German biotech and brings the total that his venture capital firm, dievini Hopp BioTech holding GmbH & Co, has injected into CureVac to €145 million ($191 million).
You may also be interested in...
Ipsen’s Palovarotene Hit By FDA Clinical Hold
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
Freshly Funded ImCheck Goes After Gamma Delta T-Cells
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis Enters ‘Transformational’ Cloud Computing Pact With Amazon
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: